IL147992A0 - Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof - Google Patents

Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Info

Publication number
IL147992A0
IL147992A0 IL14799201A IL14799201A IL147992A0 IL 147992 A0 IL147992 A0 IL 147992A0 IL 14799201 A IL14799201 A IL 14799201A IL 14799201 A IL14799201 A IL 14799201A IL 147992 A0 IL147992 A0 IL 147992A0
Authority
IL
Israel
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
IL14799201A
Other languages
English (en)
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL147992(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of IL147992A0 publication Critical patent/IL147992A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
IL14799201A 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof IL147992A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (1)

Publication Number Publication Date
IL147992A0 true IL147992A0 (en) 2002-09-12

Family

ID=9893121

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14799201A IL147992A0 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
IL147992A IL147992A (en) 2000-06-06 2002-02-04 Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody
IL195085A IL195085A0 (en) 2000-06-06 2008-11-03 Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL147992A IL147992A (en) 2000-06-06 2002-02-04 Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody
IL195085A IL195085A0 (en) 2000-06-06 2008-11-03 Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody

Country Status (42)

Country Link
US (4) US7012135B2 (sr)
EP (4) EP2308975B1 (sr)
JP (3) JP4064812B2 (sr)
KR (1) KR20020047097A (sr)
CN (1) CN1289671C (sr)
AP (1) AP2092A (sr)
AR (1) AR033978A1 (sr)
AT (1) ATE451460T1 (sr)
AU (1) AU783756B2 (sr)
BE (1) BE2010C019I2 (sr)
BG (1) BG66072B1 (sr)
BR (2) BR0106682A (sr)
CA (2) CA2380298C (sr)
CY (6) CY1109889T1 (sr)
CZ (1) CZ300737B6 (sr)
DE (3) DE60140738D1 (sr)
DK (4) DK1287140T3 (sr)
EC (1) ECSP024210A (sr)
ES (5) ES2600080T3 (sr)
FR (1) FR10C0015I2 (sr)
GB (2) GB0013810D0 (sr)
HU (4) HU230553B1 (sr)
IL (3) IL147992A0 (sr)
IS (2) IS2808B (sr)
LT (1) LT2308975T (sr)
LU (1) LU91674I2 (sr)
MX (1) MXPA01013440A (sr)
MY (1) MY136603A (sr)
NL (1) NL300982I9 (sr)
NO (4) NO334808B1 (sr)
NZ (1) NZ516596A (sr)
OA (1) OA12282A (sr)
PE (1) PE20020292A1 (sr)
PL (2) PL218516B1 (sr)
PT (4) PT1287140E (sr)
RU (1) RU2303604C2 (sr)
SI (3) SI2308975T1 (sr)
SK (1) SK288343B6 (sr)
TR (1) TR201900227T4 (sr)
TW (2) TWI353358B (sr)
WO (1) WO2001094585A1 (sr)
ZA (1) ZA200200097B (sr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
SI1944322T1 (sl) * 2002-07-19 2015-06-30 Abbvie Biotechnology Ltd. Zdravljenje s TNP alfa povezanih bolezni
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
BRPI0407511A (pt) * 2003-02-19 2006-02-14 Pharmacia Corp ésteres de polietilenoglicol ativados
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
PT1639011E (pt) * 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
JP2007501622A (ja) * 2003-08-13 2007-02-01 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドを精製するための方法
JP5544063B2 (ja) * 2003-08-13 2014-07-09 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
MX2007014440A (es) 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
AU2006255415B2 (en) 2005-06-07 2011-10-06 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ATE476176T1 (de) * 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
CA2690858A1 (en) * 2007-06-07 2008-12-18 Surmodics Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CN101939335B (zh) * 2008-02-05 2015-02-11 德勒尼克斯治疗股份公司 抗软骨退变的抗原结合多肽
JP5766598B2 (ja) * 2008-05-07 2015-08-19 アーゴス セラピューティクス インコーポレイテッド ヒトインターフェロン−αに対するヒト化抗体
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR20190133077A (ko) * 2008-06-25 2019-11-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
US8785600B2 (en) 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
JP2013520999A (ja) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
WO2011127141A1 (en) 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
ES2676877T3 (es) 2011-06-01 2018-07-25 Intrexon Actobiotics Nv Sistema de expresión policistrónica para bacterias
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US10113002B2 (en) 2012-08-13 2018-10-30 Genentech, Inc. Anti-jagged antibodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN107108691B (zh) 2014-12-22 2021-06-29 Ucb生物制药私人有限公司 蛋白质制造方法
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3402499B1 (en) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
KR20220119529A (ko) * 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019106609A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN113631574B (zh) 2019-01-31 2025-03-04 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling
CN117500816B (zh) 2021-08-26 2025-03-28 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
JP2024534603A (ja) 2021-09-24 2024-09-20 エックスブレイン バイオファーマ エービー 組換えタンパク質を発現させるためのｄｎａ構築物及び宿主細胞
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FI955798A7 (fi) * 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2218522A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
DE122004000003I2 (de) 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
HUP0202346A3 (en) 2004-11-29
ES2707714T3 (es) 2019-04-04
US20020151682A1 (en) 2002-10-17
PT2308975T (pt) 2016-11-14
NO20160694A1 (no) 2002-04-08
CZ300737B6 (cs) 2009-07-29
NL300982I9 (nl) 2019-05-06
NZ516596A (en) 2004-07-30
EP3059314B1 (en) 2018-10-24
EP2230308B1 (en) 2013-01-23
EP3059314A1 (en) 2016-08-24
DE60140738D1 (de) 2010-01-21
TWI353358B (en) 2011-12-01
BG106278A (bg) 2002-12-29
PL353960A1 (en) 2003-12-15
EP1287140A1 (en) 2003-03-05
JP2009171966A (ja) 2009-08-06
IL147992A (en) 2009-06-15
US7186820B2 (en) 2007-03-06
TR201900227T4 (tr) 2019-02-21
NO20020554L (no) 2002-04-08
CY1114143T1 (el) 2016-07-27
US20030026805A1 (en) 2003-02-06
CA2380298A1 (en) 2001-12-13
JP4476989B2 (ja) 2010-06-09
US7012135B2 (en) 2006-03-14
EP2308975A1 (en) 2011-04-13
GB2366800A (en) 2002-03-20
CY2019018I2 (el) 2020-05-29
CA2707766C (en) 2013-05-21
BG66072B1 (bg) 2011-01-31
CA2707766A1 (en) 2001-12-13
NO20131316L (no) 2002-04-08
PL212738B1 (pl) 2012-11-30
CN1383450A (zh) 2002-12-04
HK1148776A1 (en) 2011-09-16
CY2010011I1 (el) 2012-01-25
LU91674I2 (fr) 2010-05-31
NO339282B1 (no) 2016-11-21
AP2002002690A0 (en) 2002-12-31
NO20020554D0 (no) 2002-02-04
EP2308975B1 (en) 2016-08-10
FR10C0015I1 (sr) 2010-04-16
BE2010C019I2 (sr) 2020-08-20
NO2014026I2 (no) 2018-02-14
EP2230308A1 (en) 2010-09-22
DK3059314T3 (en) 2019-02-18
SI1287140T1 (sl) 2010-04-30
ES2230975B2 (es) 2007-04-16
DE122010000027I1 (de) 2010-08-12
HU230553B1 (hu) 2016-11-28
GB0013810D0 (en) 2000-07-26
DE10192353T1 (de) 2003-05-22
ECSP024210A (es) 2002-05-23
BRPI0106682B1 (pt) 2020-10-13
HK1051385A1 (en) 2003-08-01
JP2003535591A (ja) 2003-12-02
IL195085A0 (en) 2009-08-03
PL218516B1 (pl) 2014-12-31
FR10C0015I2 (fr) 2011-12-30
MY136603A (en) 2008-10-31
CY1109889T1 (el) 2012-01-25
MXPA01013440A (es) 2003-09-04
IS6217A (is) 2002-01-03
GB2366800B (en) 2005-01-19
US20080269465A1 (en) 2008-10-30
CY1118220T1 (el) 2017-06-28
US20060233800A1 (en) 2006-10-19
DK1287140T3 (da) 2010-04-19
HUP1600483A2 (sr) 2002-10-28
BR0106682A (pt) 2002-05-14
IS2808B (is) 2012-09-15
ES2403217T3 (es) 2013-05-16
AR033978A1 (es) 2004-01-21
ES2230975A1 (es) 2005-05-01
CY2019018I1 (el) 2020-05-29
NL300982I1 (sr) 2019-05-01
GB0128386D0 (en) 2002-01-16
EP1287140B1 (en) 2009-12-09
ES2337763T3 (es) 2010-04-29
TWI316088B (en) 2009-10-21
RU2303604C2 (ru) 2007-07-27
ZA200200097B (en) 2003-01-06
PL399351A1 (pl) 2012-12-17
NO2014026I1 (no) 2014-10-23
PE20020292A1 (es) 2002-05-08
CA2380298C (en) 2010-09-28
PT2230308E (pt) 2013-05-03
JP5185143B2 (ja) 2013-04-17
ATE451460T1 (de) 2009-12-15
OA12282A (en) 2006-05-11
KR20020047097A (ko) 2002-06-21
CY1121173T1 (el) 2020-05-29
NO334808B1 (no) 2014-06-02
US7402662B2 (en) 2008-07-22
SI2308975T1 (sl) 2016-11-30
JP4064812B2 (ja) 2008-03-19
WO2001094585A1 (en) 2001-12-13
DK2308975T3 (da) 2016-10-31
LU91674I9 (sr) 2019-01-03
AP2092A (en) 2010-02-28
JP2007105043A (ja) 2007-04-26
PT1287140E (pt) 2010-03-08
HUS1700013I1 (hu) 2017-08-28
ES2600080T3 (es) 2017-02-07
DK2230308T3 (da) 2013-05-06
BRPI0106682B8 (pt) 2021-05-25
LT2308975T (lt) 2016-11-10
SI2230308T1 (sl) 2013-06-28
IS3016B (is) 2019-10-15
CZ2002837A3 (cs) 2002-05-15
CN1289671C (zh) 2006-12-13
HU230669B1 (hu) 2017-07-28
HUP0202346A2 (en) 2002-10-28
HU230561B1 (hu) 2016-12-28
SK288343B6 (sk) 2016-04-01
NO341218B1 (no) 2017-09-11
US7977464B2 (en) 2011-07-12
CY2010011I2 (el) 2012-01-25
SK3152002A3 (en) 2002-07-02
TW200817430A (en) 2008-04-16
HUP1600016A2 (en) 2002-10-28
AU783756B2 (en) 2005-12-01
AU6051101A (en) 2001-12-17
PT3059314T (pt) 2019-02-01

Similar Documents

Publication Publication Date Title
HUS1700013I1 (hu) Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2868601A (en) Biaryl compounds, their preparation and their use in therapy
GB0115780D0 (en) Therapeutic molecules and uses thereof
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
HK1052013A (en) Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
AUPQ884200A0 (en) Novel therapeutic molecules and uses therefor - I
AUPR073100A0 (en) Novel therapeutic molecules and uses therefor - vii
AUPQ884400A0 (en) Novel therapeutic molecules and uses therefor - II
AUPR073300A0 (en) Novel therapeutic molecules and uses therefor - V
AUPR073200A0 (en) Novel therapeutic molecules and uses therefor - VI
AUPQ670400A0 (en) Novel therapeutic molecules and uses therefor
AU2001228686A1 (en) Biaryl compounds, their preparation and their use in therapy
GB0002559D0 (en) Virulencegene and protein and their use